Obalon Therapeutics Inc Announces Fourth Quarter and Year End 2016 Financial Results Conference Call

SAN DIEGO, Feb. 15, 2017 (GLOBE NEWSWIRE) — Obalon Therapeutics, Inc. (OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, will announce its financial results for the fourth quarter and full year ending December 31, 2016, before the market opens on Thursday, February 23, 2017.

The company will hold a conference call and simultaneous webcast at 8:30 AM Eastern Time (5:30 AM Pacific Time) on Thursday, February 23, 2017 to discuss the company’s financial results and provide a business update.  Interested parties may access the conference call by dialing (844) 889-7791 (U.S) or (661) 378 9934 (international) using passcode 69450068.  Media and individuals will be in a listen-only mode. Participants are asked to dial in a few minutes prior to the call to register for the event.  The conference call will also be webcast live at:  http://edge.media-server.com/m/p/su8exugw

A replay of the call will be available through March 2, 11:30 am EST by calling (855) 859-2056 (U.S.) or (404) 537-3406 (international), using passcode 69450068.  An archive of the webcast will be available for twelve months following the event on Obalon Therapeutics website located at http://investor.obalon.com in the “News & Events” section.

About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (OBLN), is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.

For Obalon Therapeutics Inc.

Investor Contact:
William Plovanic
Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103
The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m2 willing to follow a diet and exercise program. All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible. The most common side effects reported were mild abdominal pain and nausea which typically resolved within two weeks. You must take daily acid-blocking medicine prescribed by your doctor. For full Important Safety Information click on Safety Information and Patient Labeling.